The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors.

Autor: Fleischhacker W; Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria., Galderisi S; Department of Psychiatry, University of Naples (SUN), Naples, Italy., Laszlovszky I; Medical Division, Gedeon Richter Plc, Budapest, Hungary. Electronic address: i.laszlovszky@richter.hu., Szatmári B; Medical Division, Gedeon Richter Plc, Budapest, Hungary., Barabássy Á; Medical Division, Gedeon Richter Plc, Budapest, Hungary., Acsai K; Medical Division, Gedeon Richter Plc, Budapest, Hungary., Szalai E; Medical Division, Gedeon Richter Plc, Budapest, Hungary., Harsányi J; Medical Division, Gedeon Richter Plc, Budapest, Hungary., Earley W; Allergan, Madison, NJ, USA., Patel M; Allergan, Madison, NJ, USA., Németh G; Medical Division, Gedeon Richter Plc, Budapest, Hungary.
Jazyk: angličtina
Zdroj: European psychiatry : the journal of the Association of European Psychiatrists [Eur Psychiatry] 2019 May; Vol. 58, pp. 1-9. Date of Electronic Publication: 2019 Feb 07.
DOI: 10.1016/j.eurpsy.2019.01.015
Abstrakt: Background: Negative symptoms in schizophrenia are heterogeneous and multidimensional; effective treatments are lacking. Cariprazine, a dopamine D 3 -preferring D 3 /D 2 receptor partial agonist and serotonin 5-HT 1A receptor partial agonist, was significantly more effective than risperidone in treating negative symptoms in a prospectively designed trial in patients with schizophrenia and persistent, predominant negative symptoms.
Methods: Using post hoc analyses, we evaluated change from baseline at week 26 in individual items of the Positive and Negative Syndrome Scale (PANSS) and PANSS-derived factor models using a mixed-effects model for repeated measures (MMRM) in the intent-to-treat (ITT) population (cariprazine = 227; risperidone = 227).
Results: Change from baseline was significantly different in favor of cariprazine versus risperidone on PANSS items N1-N5 (blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking) (P < .05), but not on N6 (lack of spontaneity/flow of conversation) or N7 (stereotyped thinking). On all PANSS-derived negative symptom factor models evaluated (PANSS-Factor Score for Negative Symptoms, Liemburg factors, Khan factors, Pentagonal Structure Model Negative Symptom factor), statistically significant improvement was demonstrated for cariprazine versus risperidone (P < .01). Small and similar changes in positive/depressive/EPS symptoms suggested that negative symptom improvement was not pseudospecific. Change from baseline was significantly different for cariprazine versus risperidone on PANSS-based factors evaluating other relevant symptom domains (disorganized thoughts, prosocial function, cognition; P < .05).
Conclusions: Since items representing different negative symptom dimensions may represent different fundamental pathophysiological mechanisms, significant improvement versus risperidone on most PANSS Negative Subscale items and across all PANSS-derived factors suggests broad-spectrum efficacy for cariprazine in treating negative symptoms of schizophrenia.
(Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: